Institutional shares held 115 Million
2M calls
32.4K puts
Total value of holdings $268M
$4.66M calls
$75K puts
Market Cap $277M
118,774,000 Shares Out.
Institutional ownership 96.8%
# of Institutions 175


Latest Institutional Activity in HRTX

Top Purchases

Q1 2025
Palisade Capital Management LLC Shares Held: 5.29M ($12.3M)
Q1 2025
Palumbo Wealth Management LLC Shares Held: 124K ($289K)
Q1 2025
Cambridge Investment Research Advisors, Inc. Shares Held: 27.9K ($64.9K)
Q1 2025
Rfp Financial Group LLC Shares Held: 11.8K ($27.4K)
Q1 2025
Principal Financial Group Inc Shares Held: 115K ($269K)

Top Sells

Q1 2025
Congress Park Capital LLC Shares Held: 2.04M ($4.74M)
Q1 2025
Rhumbline Advisers Shares Held: 172K ($401K)
Q1 2025
D.A. Davidson & Co. Shares Held: 31.5K ($73.4K)
Q1 2025
Sg Americas Securities, LLC Shares Held: 69K ($161K)
Q1 2025
Bessemer Group Inc Shares Held: 1.3K ($3.03K)

About HRTX

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.


Insider Transactions at HRTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
319K Shares
From 9 Insiders
Grant, award, or other acquisition 146K shares
Exercise of conversion of derivative security 174K shares
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on HRTX

Follow HERON THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HRTX shares.

Notify only if

Insider Trading

Get notified when an Heron Therapeutics, Inc. insider buys or sells HRTX shares.

Notify only if

News

Receive news related to HERON THERAPEUTICS, INC.

Track Activities on HRTX